Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Acta Trop ; 222: 106050, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34302770

ABSTRACT

This study compared the serological and electrocardiographic evolution among patients with chronic T. cruzi infection treated during childhood or left untreated. A retrospective cohort study was conducted during a mean follow-up period of 25 years in 82 patients: half of them underwent treatment (nifurtimox 8, benznidazole 33) before being 15 years old, whereas the other half remained untreated. During the follow-up, negative seroconversion occurred in 92.7% of the treated children, while all the untreated ones remained positive for conventional serology. At baseline, 2 patients from each group had electrocardiographic abnormalities. During the study period, 4/41 (9.75%) and 9/41 (21.95%) of treated and untreated patients displayed an altered electrocardiogram, respectively. In multivariate analyses, the probability of developing electrocardiographic abnormalities was significantly reduced among treated patients (OR = 0.18, 95% CI = 0.04-0.79; p = 0.023). Electrocardiographic abnormalities attributable to Chagas cardiomyopathy were seen in 3 patients from the untreated group (complete right bundle branch block + left anterior fascicular block, frequent ventricular extrasystole, and left anterior fascicular block). The remarkable seronegativization seen in Benznidazole and Nifurtimox recipients underlines the parasiticidal effect of both compounds. Such demonstration along with the fact that CCC-related alterations were only present in the untreated group, reinforces the view of trypanocidal treatment in chronically T. cruzi-infected children as decreasing the risk for cardiomyopathy development.


Subject(s)
Chagas Disease , Nifurtimox , Nitroimidazoles , Trypanocidal Agents , Adolescent , Chagas Cardiomyopathy/epidemiology , Chagas Disease/drug therapy , Child , Follow-Up Studies , Humans , Nifurtimox/therapeutic use , Nitroimidazoles/therapeutic use , Retrospective Studies , Trypanocidal Agents/therapeutic use , Trypanosoma cruzi
2.
Acta Trop ; 218: 105908, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33789152

ABSTRACT

The immunodominant B13 protein of Trypanosoma cruzi is found on the surface of trypomastigotes and exhibits cross-reactivity with the human cardiac myosin heavy chain; for which antibodies against this parasitic antigen may be involved in the development of disease pathology. In a cohort of chronically T. cruzi-infected adults, undergoing trypanocidal treatment, or not, we, therefore, decided to evaluate the levels of anti-B13 antibodies (ELISA-B13) and its eventual relationship with heart complaints. Two hundred twenty-eight serum samples from 76 chronically infected adults with an average follow-up of 24 years were analyzed. Thirty of them had received trypanocidal treatment. Among treated patients, anti-B13 Ab levels in successive samples showed a significant decrease in reactivity as the years after treatment increased (ANOVA test, p = 0.0049). At the end of the follow-up, 36.7% became non-reactive for ELISA B13. Untreated patients did not have significant variations in the level of anti-B13 antibodies during follow-up. None of the treated patients had electrocardiographic changes compatible with chronic chagasic cardiomyopathy, whereas 21.7% of those undergoing no treatment did show such kind of pathological electrocardiogram tracings. ELISA-B13 was reactive in all cases with heart involvement. Among untreated patients, there were no significant differences in anti-B13 antibodies when comparing individuals without proven pathology with those with chronic chagasic cardiomyopathy. Although treatment with trypanocidal drugs was followed by decreased anti-B13 antibody levels, such assessment was unhelpful in differentiating the evolution of chronic chagasic heart disease.


Subject(s)
Antibodies, Protozoan/blood , Antigens, Protozoan/immunology , Chagas Disease/drug therapy , Chagas Disease/immunology , Trypanocidal Agents/therapeutic use , Adult , Animals , Argentina , Chronic Disease , Cross Reactions , Enzyme-Linked Immunosorbent Assay , Female , Follow-Up Studies , Humans , Male , Nifurtimox/therapeutic use , Nitroimidazoles/therapeutic use , Retrospective Studies , Trypanosoma cruzi , Young Adult
3.
Infect Genet Evol ; 78: 104128, 2020 03.
Article in English | MEDLINE | ID: mdl-31786340

ABSTRACT

Chronic Chagas disease affects large number of people in Latin America where it remains one of the biggest public health problems. Trypanosoma cruzi is genetically divided into seven discrete typing units (DTUs), TcI-TcVI and Tcbat, and exhibits differential distribution across vectors, host and transmission cycles. Clinical manifestations (cardiac, digestive and / or neurological) vary according to the geographical region; and the DTUs more frequently found in any of the chronic form of the disease, indeterminate or clinical, are TcI, TcII, TcV and TcVI. However, why they have a particular geographical distribution and how they affect the development of Chagas disease is still unknown. In this study, we assessed the geographic distribution of T. cruzi genotypes detected in chronic infected people from 57 localities of endemic regions of Argentina and analyzed their association with climatic variables. The prevalent DTUs detected in the whole population were TcV (47.4%) and TcVI (66.0%). TcI and TcII were identified in 5.2% each. All DTUs were detected in single and mixed infections (78.4% and 21.6%, respectively). TcV was found in infected people from localities with significantly higher average annual temperature, seasonal temperature and annual temperature range than those infected with TcVI. When we evaluated the association of DTUs with clinical manifestations of Chagas disease, the probability of finding TcVI in subjects with chronic Chagas cardiomyopathy (CCC) was higher than other DTUs, but without reaching statistical significance. Moreover, the probability of finding TcV in those who have not developed the disease after 20 years of infection was significantly higher than in CCC, either if it was present as unique DTU (reciprocal OR=4.95 95%CI: 1.42 to 17.27) (p=0.0117) or if it was also part of mixed infections (reciprocal OR=3.375; 95%CI: 1.227 to 9.276) (p=0.0264). There was no difference in the distribution of TcI between asymptomatic people and those with clinical manifestations, while TcII appeared more frequently in CCC cases, but without statiscal significance.


Subject(s)
Chagas Disease/etiology , Trypanosoma cruzi/genetics , Adult , Aged , Argentina/epidemiology , Cardiomyopathies/etiology , Chagas Disease/epidemiology , Chronic Disease , Female , Genotype , Humans , Male , Middle Aged , Prevalence , Weather
4.
Rev. Hosp. Niños B.Aires ; 62(278): 136-143, 2020.
Article in Spanish | LILACS | ID: biblio-1344050

ABSTRACT

Actualmente, la transmisión transplacentaria es la vía más frecuente de infección por Trypanosoma cruzi. El diagnóstico y tratamiento temprano de hijos infectados evita el riesgo de desarrollar miocardiopatía y las niñas dejan de ser potenciales fuentes de transmisión congénita. En este estudio se evaluó el seguimiento de hijos de mujeres infectadas por T. cruzi en Centros de Salud de la provincia de Santa Fe. Se estudiaron 19 madres y sus 51 hijos. 45% (23/51) de los hijos no habían sido estudiados previamente, y de éstos 21/23 resultaron negativos mientras que dos niñas de 3 y 7 años estaban infectadas. Los 28 niños restantes ya habían sido estudiados en los Centros de Salud, siendo positivas dos gemelas de 22 meses y una niña de 9 años; los otros 25/28 hijos no estaban infectados. Un 47% (9/19) de las madres tenían como único antecedente la serología materna positiva, y de las 4 mujeres que transmitieron la infección, tres pertenecían a este grupo. La edad promedio de diagnóstico fue: 20±6 años en las madres y 7,4±6,7 años en los hijos. Se requieren estrategias sanitarias que favorezcan el estudio para la infección por T. cruzi en mujeres antes del embarazo y el seguimiento de todos los hijos para no perder la oportunidad de tratamiento


Transplacental transmission is currently the most frequent route of infection by Trypanosoma cruzi. Early diagnosis and treatment of infected children avoids the risk of developing cardiomyopathy, and girls are no longer potential sources of congenital transmission. This study evaluated the follow-up of children of women infected with T. cruzi in Primary Care Centres of the province of Santa Fe. Nineteen mothers and their 51 children were studied. Among the 51 children, 23 had no previous diagnosis (45%). Of these, 21 were negative while 2 girls, ages 3 and 7, were infected. The remaining 28 children already had a diagnosis at the Health Centres, with 2 twins of 22 months and a 9-year-old girl who were positive; the other 25 children were not infected. Among the 19 mothers, 9 (47%) had the positive maternal serology as the only antecedent. Of the 4 women who transmitted the infection, 3 belonged to this group. The average age of diagnosis was: 20 ± 6 years in mothers and 7.4 ± 6.7 years in children. Health strategies are required to promote the detection of infected women before pregnancy and the monitoring of all children so as not to miss the opportunity for treatment


Subject(s)
Humans , Male , Female , Pregnancy , Infant , Child, Preschool , Child , Adolescent , Adult , Young Adult , Primary Health Care , Chagas Disease/congenital , Trypanocidal Agents/therapeutic use , Follow-Up Studies , Chagas Disease/drug therapy , Chagas Disease/blood , Maternal-Fetal Exchange
5.
Rev. patol. trop ; 47(3): 133-144, set. 2018. tab, ilus
Article in English | LILACS | ID: biblio-946895

ABSTRACT

The present article looks at the association between the epidemiological history of women infected with Trypanosoma cruzi and the risk of vertical transmission. Eighty-three chronically infected mothers and their 237 children were studied, using a cohort design. All patients reside in Santa Fe city, Argentina. Twenty-five women transmitted the infection to 38 children. The potential risk factors evaluated in the mothers were exposure to vector transmission, blood transfusion history, maternal seropositivity, parasitemia and age at birth of the child. 72% (18/25) of the mothers who transmitted the infection to their children, had little or no contact with the vector, while only 28% (7/25) of the mothers presented a history of medium or high risk of vector infection. The differences were significant (p < 0.05). Forty-one percent of the women who presented maternal history as the probable route of infection, transmitted the parasite to more than one child (1.86 ± 0.33; CI95% = 1.03-2.68). In addition, the most frequent history, among the women who transmitted the disease to their children, was the absence of exposure to vector transmission and transfusion with unknown maternal serology. The route of infection was probably transplacental. These observations suggest that there are family genetic characteristics involved in vertical transmission. The parasite was found in 71% of the mothers who transmitted the infection to their children and were able to perform xenodiagnoses. After controlling for the other variables, the logistic regression analysis showed that xenodiagnosis (+) is a risk factor for congenital transmission; the relative risk was 12.2 (95% confidence interval: 2.9 - 50.1). No differences were found when analyzing the mother's age and transfusion history. The highest risk of congenital transmission was associated with detectable parasitemia and less maternal exposure to the vector.


Subject(s)
Humans , Female , Pregnancy , Child , Risk Factors , Chagas Disease/transmission , Trypanosoma cruzi , Infectious Disease Transmission, Vertical , Maternal-Fetal Exchange
6.
MULTIMED ; 3(1): 7-16, ene.-abr. 1999. tab
Article in Spanish | CUMED | ID: cum-16815

ABSTRACT

Se realiza un estudio lineal y prospectivo de 360 pacientes atendidos en la Consulta de Cirugía General del Hospital General Docente Carlos Manuel de Céspedes de Bayamo, desde julio de 1994 a diciembre de 1997, por referir síntomas mamarios; teniendo como objetivos conocer el grupo de edades más afectados, el síntoma predominante, factores de riesgo presente y respuesta a los tratamientos utilizados. Pudimos conocer que los síntomas mamarios son más frecuentes en el grupo de 31-50 años, los síntomas más referidos son tumor y dolor, y la terapéutica con mejor respuesta, la que asocia vitaminas y fangoterapia, curando el tratamiento quirúrgico. Tienen significación factores de riesgo como nuliparidad, menarquia precoz y tardía, así como la no lactancia.(AU)


Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Fibrocystic Breast Disease/therapy , Fibrocystic Breast Disease/drug therapy , Fibrocystic Breast Disease/surgery , Risk Factors , Breast Neoplasms/therapy , Breast Neoplasms/drug therapy , Breast Neoplasms/surgery
7.
MULTIMED ; 2(3): 16-27, sept.-dic. 1998. tab
Article in Spanish | CUMED | ID: cum-16809

ABSTRACT

Se realiza un estudio lineal y retrospectivo de 460 fallecimientos ocurridos en el Servicio de Cirugía General del Hospital Carlos Manuel de Céspedes de Bayamo durante los años 1992-1996, teniendo como objetivos analizar la mortalidad neta y bruta, incluyendo fallecidos en el cuerpo de guardia, salón de operaciones, salas de hospitalización y unidades de cuidados intensivos e intermedios, edades más frecuentes, síndromes, etiología, así como causas de muerte. Se encontró que el mayor número de fallecidos tenían por encima de 61 años (65,22 por ciento), el síndrome oclusivo (18,04) y las neoplasias (23,04 por ciento) entre operaciones urgentes y no urgentes respectivamente, son las entidades que aportan mayor número de fallecidos. La principal causa de muerte es la sepsis (41,96 por ciento). Sólo se operó el 76,09 por ciento de los pacientes ingresados en el período.(AU)


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Cause of Death , Surgery Department, Hospital/statistics & numerical data , Sepsis/mortality
SELECTION OF CITATIONS
SEARCH DETAIL
...